Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.98 EUR
−35.32 M EUR
0.00 EUR
32.11 M
About Soleno Therapeutics, Inc.
Sector
CEO
Anish Bhatnagar
Headquarters
Redwood City
Website
Founded
1999
FIGI
BBG00GX8QKC4
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6XC is 52.80 EUR — it has decreased by −2.33% in the past 24 hours. Watch SOLENO THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SOLENO THERAPEUTICS INC stocks are traded under the ticker 6XC.
6XC stock has risen by 12.58% compared to the previous week, the month change is a 6.98% rise, over the last year SOLENO THERAPEUTICS INC has showed a 105.45% increase.
We've gathered analysts' opinions on SOLENO THERAPEUTICS INC future price: according to them, 6XC price has a max estimate of 86.77 EUR and a min estimate of 62.51 EUR. Watch 6XC chart and read a more detailed SOLENO THERAPEUTICS INC stock forecast: see what analysts think of SOLENO THERAPEUTICS INC and suggest that you do with its stocks.
6XC stock is 5.49% volatile and has beta coefficient of 1.23. Track SOLENO THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is SOLENO THERAPEUTICS INC there?
Today SOLENO THERAPEUTICS INC has the market capitalization of 2.40 B, it has increased by 6.13% over the last week.
Yes, you can track SOLENO THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
SOLENO THERAPEUTICS INC is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
6XC earnings for the last quarter are −1.64 EUR per share, whereas the estimation was −0.54 EUR resulting in a −202.48% surprise. The estimated earnings for the next quarter are −0.99 EUR per share. See more details about SOLENO THERAPEUTICS INC earnings.
SOLENO THERAPEUTICS INC revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
6XC net income for the last quarter is −68.81 M EUR, while the quarter before that showed −20.40 M EUR of net income which accounts for −237.27% change. Track more SOLENO THERAPEUTICS INC financial stats to get the full picture.
No, 6XC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 42.00 employees. See our rating of the largest employees — is SOLENO THERAPEUTICS INC on this list?
Like other stocks, 6XC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOLENO THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SOLENO THERAPEUTICS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SOLENO THERAPEUTICS INC stock shows the buy signal. See more of SOLENO THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.